Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer
28 Janvier 2019 - 3:23PM
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the
appointment of Sheldon Koenig as executive vice president and chief
commercial officer, effective immediately. Mr. Koenig brings to his
new role more than three decades of global commercial leadership
and operations experience. He will report to Scott Garland,
president and chief executive officer, and will serve as a member
of the Portola Executive Committee.
“With a tremendous track record building and
leading strong commercial teams in the successful launch of
hospital-based products and thrombotic medicines, Sheldon is
uniquely qualified to take on this critical role,” said Mr.
Garland. “I am confident in his ability to deliver on our goals for
the launch of Andexxa, and we are pleased to add him to our
talented leadership team.”
Prior to joining Portola, Mr. Koenig was senior
vice president and head of the cardiovascular franchise for Sanofi
where he led U.S. business operations and product launches in more
than 20 countries. Previously, he served as vice president and
global brand leader for the cardiovascular division of Merck &
Co, Inc. where, for more than 25 years, he took on roles of
increasing responsibility within the Company’s cardiovascular and
thrombosis franchises.
“We have the potential to make a profound impact
on the lives of patients worldwide and I am pleased to have
the opportunity to contribute to that mission,” said Mr. Koenig.
“Given the rapid and increasing growth in the use of Factor Xa
inhibitors, there is a clear and significant need for Andexxa. I
look forward to working with the team to deliver on the ambitious
goals we have set for Andexxa on behalf of patients.”
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are Andexxa®
[coagulation factor Xa (recombinant), inactivated-zhzo], the first
and only antidote for patients treated with rivaroxaban and
apixaban when reversal of anticoagulation is needed due to
life-threatening or uncontrolled bleeding, and
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor for the prevention of VTE in adult patients
hospitalized for an acute medical illness. The company also is
advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of
hematologic cancers.
Forward-Looking Statements Statements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the growth potential for Portola
and potential of Portola’s products. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
risk that physicians, patients and payers may not see the benefits
of utilizing Andexxa or Bevyxxa for the indications which they are
approved; our ability to continue to manufacture our products and
to expand approved manufacturing facilities; the possibility of
unfavorable results from additional clinical trials involving
Andexxa; the risk that the EMA may not approve Andexxa in the
currently anticipated timelines or at all, and that any marketing
approvals or reimbursement limitations may have significant
limitations on its use; the risk that Portola may not obtain
additional regulatory approvals necessary to expand approved
indications for Andexxa; our expectation that we will incur losses
for the foreseeable future and will need additional funds to
finance our operations; the accuracy of our estimates regarding
expenses and capital requirements; our ability to successfully
build a hospital-based sales force and commercial infrastructure;
our ability to obtain and maintain intellectual property protection
for our product candidates; and our ability to retain key
scientific or management personnel. These and other risks and
uncertainties are described more fully in our most recent filings
with the Securities and Exchange Commission, including our
most recent quarterly report on Form 10-Q. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
|
|
|
|
|
Investor
Contact: Cara Miller Portola
Pharmaceuticals ir@portola.com |
|
Media
Contact:Julie Normart Pure Communications
jnormart@purecommunications.com |
|
|
|
|
|
|
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024